Recombinant Human-C1 Inhibitor Is Effective and Safe for Repeat Hereditary Angioedema Attacks

Journal of Allergy and Clinical Immunology: In Practice

Volumn 3, Issue 3, 2015, Pages 417-423

  Li, H Henry ^a   Moldovan, Dumitru ^b   Bernstein, Jonathan A ^c   Reshef, Avner ^d   Porebski, Gregor ^e   Stobiecki, Marcin ^e   Baker, James ^f   Levy, Robyn ^g   Relan, Anurag ^h   Riedl, Marc ⁱ  

^a Institute for Asthma and Allergy   (United States)

^b UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c UNIVERSITY OF CINCINNATI   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^f Baker Asthma Allergy and Dermatology   (United States)

^g Family Allergy and Asthma Center   (United States)

^h Pharming Group NV   (Netherlands)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hereditary angioedema; Recombinant human C1 esterase inhibitor; Repeat attacks

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; SERPING1 PROTEIN, HUMAN;

ADULT; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BACKACHE; CHILL; CLINICAL ARTICLE; COUGHING; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HUMAN; LACRIMATION DISORDER; MALE; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RELAPSE; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SYMPTOM; THROMBOSIS; TREATMENT EFFECT QUESTIONNAIRE; ANGIOEDEMAS, HEREDITARY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; EUROPE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; ISRAEL; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INACTIVATOR PROTEINS; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; ISRAEL; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; REMISSION INDUCTION; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84942108450     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.12.013     Document Type: Article

References (22)

1. Bork K., Davis-Lorton M. Overview of hereditary angioedema caused by C1-inhibitor deficiency: assessment and clinical management. Eur Ann Allergy Clin Immunol 2013, 45:7-16.
2. Bork K., Meng G., Staubach P., Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006, 119:267-274.
3. Bernstein J.A. HAE update: epidemiology and burden of disease. Allergy Asthma Proc 2013, 34:3-6.
4. Lumry W.R., Castaldo A.J., Vernon M.K., Blaustein M.B., Wilson D.A., Horn P.T. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010, 31:407-414.
5. Craig T., Aygören-Pürsün E., Bork K., Bowen T., Boysen H., Farkas H., et al. WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J 2013, 5:182-199.
6. Cicardi M., Craig T.J., Martinez-Saguer I., Hébert J., Longhurst H.J. Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration. Int Arch Allergy Immunol 2013, 161:3-9.
7. Frank M.M. Recombinant and plasma-purified human c1 inhibitor for the treatment of hereditary angioedema. World Allergy Organ J 2010, 3:S29-S33.
8. Gandhi P.K., Gentry W.M., Bottorff M.B. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 2012, 32:902-909.
9. Maksimenko O.G., Deykin A.V., Khodarovich Y.M., Georgiev P.G. Use of transgenic animals in biotechnology: prospects and problems. Acta Naturae 2013, 5:33-46.
10. van Veen H.A., Koiter J., Vogelezang C.J., van Wessel N., van Dam T., Velterop I., et al. Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits. J Biotechnol 2012, 162:319-326.
11. Farrell C., Hayes S., Relan A., van Amersfoort E.S., Pijpstra R., Hack C.E. Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. Br J Clin Pharmacol 2013, 76:897-907.
12. van Doorn M.B., Burggraaf J., van Dam T., Eerenberg A., Levi M., Hack C.E., et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005, 116:876-883.
13. Zuraw B., Cicardi M., Levy R.J., Nujens J.H., Relan A., Visscher S., et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010, 126:821-827.e14. 821-7.e14.
14. Riedl M.A., Levy R.J., Suez D., Lockey R.F., Baker J.W., Relan A., et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann Allergy Asthma Immunol 2013, 110:295-299.
15. Moldovan D., Reshef A., Fabiani J., Kivity S., Toubi E., Shlesinger M., et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy 2012, 42:929-935.
16. Riedl M.A., Bernstein J.A., Li H., Reshef A., Lumry W., Moldovan D., et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol 2014, 112:163-169.e1. 163-9.e1.
17. Caballero T., Aygören-Pürsün E., Bygum A., Beusterien K., Hautamaki E., Sisic Z., et al. The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. Allergy Asthma Proc 2014, 35:47-53.
18. Jolles S., Williams P., Carne E., Mian H., Huissoon A., Wong G., et al. A UK national audit of hereditary and acquired angioedema. Clin Exp Immunol 2014, 175:59-67.
19. Li H., Riedl M., Bernstein J., Lumry W., Reshef A., Moldovan D., et al. Sustained response following acute treatment of hereditary angioedema attacks with recombinant human C1 esterase inhibitor [abstract]. J Allergy Clin Immunol 2014, 133:131.
20. Caballero T. Efficacy assessments in randomized controlled studies of acute therapy for hereditary angioedema. J Clin Immunol 2012, 32:1204-1212.
21. McMillan C.V., Speight J., Relan A., Bellizzi L., Haase G., Cicardi M. Content validity of visual analog scales to assess symptom severity of acute angioedema attacks in adults with hereditary angioedema: an interview study. Patient 2012, 5:113-126.
22. Hack C.E., Mannesse M., Baboeram A., Oortwijn B., Relan A. Immunogenicity assessment of recombinant human c1-inhibitor: an integrated analysis of clinical studies. BioDrugs 2012, 26:303-313.